Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial
Information source: Kaiser Permanente
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Uterine Hemorrhage; Menorrhagia
Intervention: Provera (Drug); Combination Birth Control pills (Drug)
Sponsored by: Kaiser Permanente
Official(s) and/or principal investigator(s):
Malcolm G Munro, M.D., Principal Investigator, Affiliation: Southern California Permanente Medical Group
Romie Basu, MD, Principal Investigator, Affiliation: Southern California Permanente Medical Group
To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera)
and a multidose, monophasic combination oral contraceptive in the treatment of
hemodynamically stable women with non-gestational, acute uterine bleeding.
Official title: Treatment of Non-Gestational Acute Uterine BleedingComparing Oral Medroxyprogesterone Acetate and Monophasic Oral Contraceptives Containing Norethindrone and Ethinyl Estradiol
Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
The avoidance of unscheduled surgery in the 28-day follow-up period.
To calculate the time requred from initiation of medical therapy until the cessation bleeding, comparing MPA to monophasic combination oral contraceptive pills.
The assessment of pad and tampon counts.
The assessment of hemoglobin levels, symptoms and side effects (ie: cramping, nausea and bloating) and patient satifaction with medical therapy.
Acute uterine bleeding, unrelated to pregnancy, is a relatively common problem that causes
many reproductive-aged women to requite emergent medical and/or surgical intervention.
Although the traditional approaches have generally been surgical in nature, many
practitioners utilize medical methods to arrest the bleeding. However, despite widespread
use, there exists a paucity of information regarding the effectiveness, side-effects, and
patient satisfaction associated with the commonly-used medical regimens. (b) The purpose of
the study is to compare the efficacy of multidose medroxyprogesterone acetate and a
multidose, monophasic combined oral contraceptive in the treatment of hemodvnamically-stable
women with non-gestational, acute uterine bleeding.
(c) Non-pregnant, hemodynamically-stable, reproductive-aged, women, over the age of IS, who
present either to the emergency area or to KP practitioner's offices with acute uterine
bleeding, will be considered for eligibility. If, following a full exam and medically
appropriate investigations medical management is deemed appropriate, they will be approached
by a member of the investigating team for possible inclusion into the study. Following
informed consent, patients will be randomized to receive either medroxyprogesterone acetate
(20 mg three times daily for 7 days) or monophasic oral contraceptive containing I mg of
norethindrone and 35 ug of ethinyl estradiol (three dines daily for seven days). Following
the seven days of therapy, those randomized to MPA will continue with 20 mg per day for three
weeks while those randomized to oral contraceptives will take one pill per day for three
weeks, each completing a total of four weeks of therapy. The primary outcome will be the
number of days until cessation of bleeding. Other outcomes measured will include pad and
tampon counts, and hemoglobin levels. Chi square tests and student t will be used to evaluate
differences between the two treatment groups. The hope is that this study will elucidate on
the efficacy of the two regimens.
Minimum age: 18 Years.
Maximum age: 65 Years.
Non-pregnant Hemodynamically stable Reproductive-aged women >18 years Present with acute
Pregnant Non-hemodynamically stable <18 years
Locations and Contacts
Kaiser Permanente Sunset, Los Angeles, California 90027, United States
Starting date: April 2003
Ending date: June 2005
Last updated: March 24, 2008